Background In most resource limited settings, new tuberculosis (TB) patients are usually treated as outpatients. We sought to investigate the reasons for hospitalisation and the predictors of poor treatment outcomes and mortality in a cohort of hospitalized new TB patients in Kampala, Uganda Methods and findings Ninety-six new TB patients hospitalised between 2003 and 2006 were enrolled and followed for two years. Thirty two were HIV-uninfected and 64 were HIV-infected. Among the HIV-uninfected, the commonest reasons for hospitalization were low Karnofsky score (47%) and need for diagnostic evaluation (25%). HIV-infected patients were commonly hospitalized due to low Karnofsky score (72%), concurrent illness (16%) and diagnostic evaluation (14%). Eleven HIV uninfected patients died (mortality rate 19.7 per 100 person-years) while 41 deaths occurred among the HIV-infected patients (mortality rate 46.9 per 100 person years). In all patients an unsuccessful treatment outcome (treatment failure, death during the treatment period or an unknown outcome) was associated with duration of TB symptoms, with the odds of an unsuccessful outcome decreasing with increasing duration. Among HIV-infected patients, an unsuccessful treatment outcome was also associated with male sex (P = 0.004) and age (P = 0.034). Low Karnofsky score (aHR = 8.93, 95% CI 1.88 – 42.40, P = 0.001) was the only factor significantly associated with mortality among the HIV-uninfected. Mortality among the HIV-infected was associated with the composite variable of CD4 and ART use, with patients with baseline CD4 below 200 cells/μL who were not on ART at a greater risk of death than those who were on ART, and low Karnofsky score (aHR = 2.02, 95% CI 1.02 – 4.01, P = 0.045). Conclusion Poor health status is a common cause of hospitalisation for new TB patients. Mortality in this study was very high and associated with advanced HIV Disease and no use of ART.
References
[1]
Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593. doi: 10.1002/14651858.cd009593.pub2
[2]
Mosimaneotsile B, Talbot EA, Moeti TL, Hone NM, Moalosi G, et al. (2003) Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 362: 1551–1552. doi: 10.1016/s0140-6736(03)14745-9
[3]
Corbett EL, Marston B, Churchyard GJ, De Cock KM (2006) Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367: 926–937. doi: 10.1016/s0140-6736(06)68383-9
[4]
Lawn SD, Wood R (2006) The epidemic of HIV-associated tuberculosis in sub-Saharan Africa: does this also impact non-HIV-infected individuals? Aids 20: 1787–1788. doi: 10.1097/01.aids.0000242831.27990.da
[5]
Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181: 80–86. doi: 10.1164/rccm.200907-0989oc
[6]
Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, et al. (2000) Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 14: 1219–1228. doi: 10.1097/00002030-200006160-00020
[7]
Palmieri F, Girardi E, Pellicelli AM, Rianda A, Bordi E, et al. (2002) Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection 30: 68–74. doi: 10.1007/s15010-002-2062-9
[8]
Jones-Lopez EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, et al. (2011) Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med 8: 15. doi: 10.1371/journal.pmed.1000427
[9]
Yen YF, Yen MY, Shih HC, Deng CY (2012) Risk factors for unfavorable outcome of pulmonary tuberculosis in adults in Taipei, Taiwan. Trans R Soc Trop Med Hyg 106: 303–308. doi: 10.1016/j.trstmh.2012.01.011
[10]
Naidoo S, Douglas D (2008) Admission trends of adult TB patients at one of the largest tuberculosis hospitals in South Africa: from 2001 to 2003. Southern African Journal of Epidemiology and Infection 22: 8–12.
[11]
Abos-Hernandez R, Olle-Goig JE (2002) Patients hospitalised in Bolivia with pulmonary tuberculosis: risk factors for dying. Int J Tuberc Lung Dis 6: 470–474.
[12]
Duarte EC, Bierrenbach AL, Barbosa da Silva J Jr, Tauil PL, de Fatima Duarte E (2009) Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 63: 233–238. doi: 10.1136/jech.2008.078972
[13]
Volmink J, Garner P (2007) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev: CD003343.
[14]
Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, et al. (2005) Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. Aids 19: 163–168. doi: 10.1097/00002030-200501280-00008
[15]
Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, et al. (2008) Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. Bmj 337: a257. doi: 10.1136/bmj.a257
[16]
Dheda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 190: 1670–1676. doi: 10.1086/424676
[17]
Tabarsi P, Saber-Tehrani AS, Baghaei P, Padyab M, Mansouri D, et al. (2009) Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 12: 14. doi: 10.1186/1758-2652-12-14
[18]
Davis JL, Worodria W, Kisembo H, Metcalfe JZ, Cattamanchi A, et al. (2010) Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS One 5: e9859. doi: 10.1371/journal.pone.0009859
[19]
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 161: 1376–1395. doi: 10.1164/ajrccm.161.4.16141
[20]
(2010) MANUAL OF THE NATIONAL TUBERCULOSIS AND. LEPROSY PROGRAMME. 2 nd. EDITION. 2010 Kampala.
[21]
(2010) Stop TB initiative. Treatment of tuberculosis: guidelines 2010: World Health Organization.
[22]
Erhabor GE, Adewole OO, Ogunlade O (2006) A five-year review of tuberculosis mortality amongst hospitalised patients in Ile-Ife. Indian J Chest Dis Allied Sci 48: 253–256.
[23]
Hansel NN, Merriman B, Haponik EF, Diette GB (2004) Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest 126: 1079–1086. doi: 10.1378/chest.126.4.1079
[24]
Lubart E, Lidgi M, Leibovitz A, Rabinovitz C, Segal R (2007) Mortality of patients hospitalized for active tuberculosis in Israel. The Israel Medical Association journal: IMAJ 9: 870.
[25]
(1996) Bactec 460 System: Product and Procedure Manual. Sparks, MD: Becton, Dickenson, and Company.
[26]
(1999) Bactec MGIT 960 system user's manual. Sparks, MD: Becton, Dickenson, and Company.
[27]
Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, et al. (2006) Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis 10: 1262–1267.
[28]
World Health Organization. (2009) Treatment of tuberculosis: guidelines — 4th ed. Geneva: World Health Organization.
[29]
Greenland S (2008) The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 27: 199–206.
[30]
Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515–526. doi: 10.1093/biomet/81.3.515
[31]
Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, et al. (2011) Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana. Trans R Soc Trop Med Hyg 105: 675–682. doi: 10.1016/j.trstmh.2011.07.017
[32]
van't Hoog AH, Williamson J, Sewe M, Mboya P, Odeny LO, et al. (2012) Risk factors for excess mortality and death in adults with tuberculosis in Western Kenya. Int J Tuberc Lung Dis 16: 1649–1656. doi: 10.5588/ijtld.12.0135
[33]
Henegar C, Behets F, Vanden Driessche K, Tabala M, Bahati E, et al. (2012) Mortality among tuberculosis patients in the Democratic Republic of Congo. Int J Tuberc Lung Dis 16: 1199–1204. doi: 10.5588/ijtld.11.0613
[34]
Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin Pde T (2010) Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung 188: 33–41. doi: 10.1007/s00408-009-9224-9
[35]
Waitt CJ, Squire SB (2011) A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 15: 871–885. doi: 10.5588/ijtld.10.0352
[36]
Lopez-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, et al. (2007) Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 165: 1134–1142. doi: 10.1093/aje/kwk116
[37]
Rao VK, Iademarco EP, Fraser VJ, Kollef MH (1998) The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 114: 1244–1252. doi: 10.1378/chest.114.5.1244
[38]
Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, et al. (2000) Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 4: 931–939.
[39]
Shimazaki T, Marte SD, Saludar NR, Dimaano EM, Salva EP, et al. (2013) Risk factors for death among hospitalised tuberculosis patients in poor urban areas in Manila, The Philippines. Int J Tuberc Lung Dis 17: 1420–1426. doi: 10.5588/ijtld.12.0848
[40]
Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, et al. (2002) Delay in diagnosis among hospitalized patients with active tuberculosis—predictors and outcomes. Am J Respir Crit Care Med 165: 927–933. doi: 10.1164/ajrccm.165.7.2107040
[41]
Pablos-Mendez A, Sterling TR, Frieden TR (1996) The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 276: 1223–1228. doi: 10.1001/jama.276.15.1223
[42]
Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492–1501. doi: 10.1056/nejmoa1014181
[43]
Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365: 1471–1481. doi: 10.1056/nejmoa1013911
[44]
Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine 365: 1482–1491. doi: 10.1056/nejmoa1013607
[45]
Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Effect of initiating antiretroviral therapy during tuberculosis treatment in HIV-infected individuals: results of a randomized controlled trial in TB-HIV co-infected patients in South Africa (SAPiT Study). N Engl J Med 362: 697–706.
